Castle Biosciences, Inc. (CSTL)
Chart Events
Performance Outlook
| Previous Close | 68.17 |
| Open | 68.45 |
| Bid | 58.00 x 1200 |
| Ask | 65.50 x 800 |
| Day's Range | 65.22 - 68.45 |
| 52 Week Range | 26.13 - 107.69 |
| Volume | 185,840 |
| Avg. Volume | 317,580 |
| Market Cap | 1.636B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.21 |
| Earnings Date | Mar 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 85.80 |
Fair Value
Related Research
- Business Wire
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress
Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma.
- Business Wire
Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma
Castle presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP).
- Business Wire
Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced data from an independent, prospective study published in the American Journal of Surgery demonstrating DecisionDx®-Melanoma’s utility for prediction of outcomes in patients with cutaneous melanoma. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.
